#10 – Pneumovax |
Pneumococcal infection |
2013 – $653 million |
2012 – $580 million |
Marketed by Merck and Sanofi Pasteur MSD |
#9 – RotaTeq |
Rotaviral gastroenteritis |
2013 – $691 million |
2012 – $648 million |
Marketed by Merck and Sanofi Pasteur MSD |
#8 – Zostavax |
Herpes Zoster (Shingles) |
2013 – $826 million |
2012 – $ N/A |
Marketed by Merck and Sanofi Pasteur MSD |
#7 – Hepatitis vaccine franchise |
Hepatitis A, Hepatitis B |
2013 – $984 million |
2012 – $986 million |
Marketed by GSK |
#6 – Infanrix/Pediarix |
Diptheria, Tetanus, Pertussis, Hepatitis B, Polio |
2013 – $1.349 billion |
2012 – $1.83 billion |
Marketed by GSK |
Top selling vaccines 2013 #5 to #1 >